leadf
logo-loader
viewNetscientific PLC

Netscientific business Vortex Bio kicks off lung cancer proof of concept trial

These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs).

picture of cells
Vortex aims to collect circulating turmour cells

NetScientific PLC (LON:NSCI) portfolio company Vortex Biosciences has initiated two clinical research studies with Californian university UCLA in patients with Non-Small Cell Lung Cancer (NSCLC).

These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs).

This first 60 patient study is intended to determine if cancer causing EGFR mutations can be identified in CTCs isolated and collected using Vortex’sVTX-1 Liquid Biopsy System from NSCLC patient samples.

The second 100 NSCLC patient study is intended to show CTCs isolated using the VTX-1 Liquid Biopsy System are compatible with the PD-L1 biomarker, which can help identify patients suitable for immunotherapy treatment.

Francois  Martelet, who is chairman of Vortex a well as being NetScientific’s chief executive, said  said: “These two proof of principle clinical research studies, in collaboration with UCLA, are a vital step in clinically validating and thus commercialising the company's first product, the VTX-1 system.”

Quick facts: Netscientific PLC

Price: 49 GBX

AIM:NSCI
Market: AIM
Market Cap: £7.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

NetScientific plc chief hails progress at Vortex Biosciences

NetScientific plc (LON:NSCI) chief executive and chairman Francois Martelet hailed recent news from portfolio company Vortex Biosciences as a "very important" milestone. Vortex has been awarded a CE Mark for its circulating tumour cell (CTC) capture system and has registered a Class I...

on 11/07/2016

2 min read